HINGHAM, Mass., Aug. 10, 2017 -- Microbot Medical Inc. (Nasdaq:MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, will release second quarter 2017 financial and operational results on Monday, August 14, 2017 after the close of the U.S. markets.
The Company will host a conference call and webcast on Monday, August 14, 2017 at 5:00 pm ET. For both “listen-only” participants and those participants who wish to take part in the question-and-answer portion of the call, the dial-in number is 888-208-1814 (U.S./Canada) or 719-325-2154 (international) and providing the Conference ID 6914000. A live webcast and subsequent archived replay may be accessed via the ‘Investors’ section, under ‘Presentations and Resources’ of the Company’s website at www.microbotmedical.com.
A replay of the conference call will be available for seven business days beginning about two hours after the conclusion of the live call, by dialing 888-203-1112 (U.S./Canada) or +1 719-457-0820 (international) and providing the Conference ID 6914000. An archived webcast will also be available and may be accessed in the ‘Investors’ section of the Company’s website at www.microbotmedical.com.
About Microbot Medical Inc.
Microbot, which was founded in 2010 and commenced operations in 2011, became a NASDAQ listed company on November 28, 2016. The Company specializes in transformational micro-robotic medical technologies leveraging the natural and artificial lumens within the human body. Microbot’s current platforms, ViRob and TipCAT, are comprised of two highly advanced micro-robotic technologies, from which the Company is currently developing its first two product candidates: the Self Cleaning Shunt, or SCS, for the treatment of hydrocephalus and Normal Pressure Hydrocephalus, or NPH; and a self-propelling, semi-disposable endoscope that is being developed initially for use in colonoscopy procedures. Further information about Microbot Medical is available at http://www.microbotmedical.com.
The ViRob technology is a revolutionary autonomous crawling micro-robot which can be controlled remotely or within the body. Its miniature dimensions allow it to navigate and crawl in different spaces within the human body, including blood vessels, the digestive tract and the respiratory system. Its unique structure gives it the ability to move in tight spaces and curved passages as well as the ability to remain within the human body for prolonged time. To learn more about ViRob please visit http://www.microbotmedical.com/technology/virob/.
TipCAT is a transformational self-propelled, flexible, and semi-disposable endoscope providing see & treat capabilities within tubular lumens in the human body such as the colon, blood vessels, and the urinary tract. Its locomotion mechanism is perfectly suitable to navigate and crawl through natural & artificial tubular lumens, applying the minimal necessary pressure to achieve the adequate friction required for gentle, fast, and safe advancement within the human body. To learn more about TipCAT visit http://www.microbotmedical.com/technology/tipcat/.
Investor Contacts: EVC Group Michael Polyviou/Doug Sherk - Investors [email protected]; [email protected] (646) 445-4800


Tesla Launches New Model Y Variant in the US Starting at $41,990
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations
Hyundai Motor Lets Russia Plant Buyback Option Expire Amid Ongoing Ukraine War
Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure
Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
NRW Holdings Shares Surge After Securing Major Rio Tinto Contract and New Project Wins
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 



